Manganese, a Likely Cause of 'Parkinson's in Cirrhosis', a Unique Clinical Entity of Acquired Hepatocerebral Degeneration
Open Access
- 14 September 2020
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 12 (9)
Abstract
With idiopathic Parkinson's disease being a common entity, parkinsonism in acquired hepatocerebral degeneration (AHD) in the context of Manganese (Mn) has gained importance in recent years. An insight into the pathomechanisms behind this disease has been put forth. How can Mn as a divalent metal exert its effect in leading to chronic neurodegenerative disorder? Secondary to decreased excretion in liver cirrhosis, Mn significantly alters the striatal dopaminergic system. Management of this debilitating disease also focuses on different aspects where Mn has been involved in the pathogenesis. We have put forth the details behind Mn effects in Parkinson’s, which will be a guide for better understanding and management of this disease. A literature search was performed using PubMed as a sole database, and all the articles were peer-reviewed. The author tried to follow the PRISMA guidelines. Inclusion criteria were set for 10 years, with most studies with in the last seven years. All types of study designs were included relevant to the topic, clearly delineating the pathomechanisms of Mn in the disease and also its management. After extensive research, through the PubMed database, we found that Parkinson's disease is one of the neurological complications in advanced liver cirrhosis. Mn is an essential element behind its pathogenesis; it works at different cellular levels to promote neurotoxicity. From its influx to its effects on dopamine transporters (DAT), where it disrupts dopamine homeostasis also altering postsynaptic dopamine (D2) receptors, it disrupts mitochondria and the endoplasmic reticulum (ER) promotes oxidative stress and neuroinflammation. Misfolding of alpha-synuclein (α-Syn) is promoted on chronic exposure to Mn where α-Syn from being neuroprotective becomes neurotoxic. It also alters glutaminergic and gabaergic neurotransmission. In a nutshell, the diversity of its effect on nigrostriatal denervation is challenging. The importance of neuroimaging and various approaches to management is also discussed. AHD, an uncommon entity in advanced liver cirrhosis, needs more awareness so that it can be diagnosed earlier and better therapeutic options can be sought. Our study highlighted Mn mechanisms behind this clinical entity, putting forth grounds for a better understanding of this disease. Advanced research targeting Mn for managing this disease will be revolutionary.Keywords
This publication has 50 references indexed in Scilit:
- Oxidative stress involvement in manganese-induced alpha-synuclein oligomerization in organotypic brain slice culturesToxicology, 2013
- Manganese toxicity in the central nervous system: the glutamine/glutamate‐γ‐aminobutyric acid cycleJournal of Internal Medicine, 2013
- Manganese transport via the transferrin mechanismNeuroToxicology, 2013
- Reduced Uptake of FDOPA PET in End-stage Liver Disease With Elevated Manganese LevelsArchives of Neurology, 2012
- Protective effects of antioxidants and anti-inflammatory agents against manganese-induced oxidative damage and neuronal injuryToxicology and Applied Pharmacology, 2011
- Dopamine release mediated by the dopamine transporter, facts and consequencesJournal of Neurochemistry, 2011
- Effects of manganese on tyrosine hydroxylase (TH) activity and TH-phosphorylation in a dopaminergic neural cell lineToxicology and Applied Pharmacology, 2011
- Chronic acquired hepatocerebral degeneration: effects of liver transplantation on neurological manifestationsNeurological Sciences, 2011
- Induction of FPN1 transcription by MTF-1 reveals a role for ferroportin in transition metal effluxBlood, 2010
- Ferroportin is a manganese‐responsive protein that decreases manganese cytotoxicity and accumulationJournal of Neurochemistry, 2010